Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 9 LDP Leader Candidates Showcase Pharma Agendas in Campaign
September 17, 2024
- FY2025 Budget Request Would Add 7 PMDA Reviewers for Startup Consultations
September 13, 2024
- Japan Approves Meiji’s JN.1-Directed COVID-19 Vaccine
September 13, 2024
- MHLW Lays Out Updated Discussion Timeline for PMD Act Amendment
September 13, 2024
- Trodelvy Nears Japan Approval as It Sails through Panel Review
September 13, 2024
- Kamikawa Runs for LDP Presidency, Resolved to Empower Healthcare Realm
September 12, 2024
- Mounjaro to Keep Price after CEA as Lilly’s Appeal for Raise Nixed
September 12, 2024
- Antivirals Push Up Japan’s Drug Spending in FY2023: MHLW
September 12, 2024
- Ex-Minister Kato Joins Fray in LDP Race, Pledges Inflation-Linked Drug Prices
September 11, 2024
- MHLW Proposes Periodic Survey of Vaccine Prices in Japan
September 11, 2024
- Takaichi Vows to Bolster Japan’s Self-Sufficiency of Drugs, Vaccines in LDP Race
September 11, 2024
- Japan Extends Re-Examination Period for Entyvio, Zintus
September 11, 2024
- AMED Research Exploring Low-Cost Method to Analyze Nitrosamine Impurities
September 11, 2024
- First Drug Delisting in Simplified Process Slated for March-End 2026: MHLW
September 10, 2024
- Eisai COO Calls for LDP Collaboration in AD Diagnosis, Treatment
September 10, 2024
- MHLW to Accept English Dossiers from Foreign Makers
September 9, 2024
- MHLW Proposes Scope of Observational Research Subject to Clinical Trials Act
September 9, 2024
- MHLW Floats 3 Perspectives to Codify Rules for Drug Supply Management
September 9, 2024
- PMDA-Led Inspections Will Help Straighten Up Generic Makers: MHLW Councilor
September 6, 2024
- MOF Intent on Expanding Scope of Off-Year Revision in 2025: Budget Examiner
September 6, 2024
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…